Related Experiment Video
Updated: Dec 17, 2025
Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
Intralipid therapy for unexplained recurrent miscarriage and implantation failure: Case-series and literature review
Léo Plaçais1, Kamilla Kolanska2, Yasmine Ben Kraiem2
1AP-HP, Hôpital Saint Antoine, service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Faculté de Médecine Sorbonne Université, F-75012, Paris, France; Sorbonne Universités, UPMC Université Paris 06, UMR 7211, F-75005, Paris, France.
Introduction:
In retrospective cohort study of women with unexplained recurrent implantation failure (RIF) and miscarriage (RM), we analyzed the efficacy and safety of intralipid therapy to obtain a live birth.
Patients And Methods:
Women with unexplained RM and/or RIF were included from 2015 to 2018 from three French university hospitals.
Results:
Among 187 women treated for unexplained recurrent miscarriages and implantation failures, 26 women with median age of 36 years (29-43) received intralipid therapy. Among these 26 women, 10 women with a median age of 33 years (31-40) had a history of spontaneous recurrent miscarriages, with a median of 5 (4-8) previous miscarriages. Live births occurred in 7 (70 %) pregnancies under intralipids and were significantly more frequent than in women with recurrent miscarriages who did not receive intralipid therapy (n = 20, p = 0.02). Age, number of previous miscarriages, and additional therapies did not significantly differ between the two groups. Among the 26 included women, 16 had a history of recurrent implantation failures, with median age of 37 years (29-43) and median 9.5 (3-19) embryo transfers. Clinical pregnancy occurred in 9 (56 %) women receiving intralipids after embryo transfers under intralipids among which 5 (55 %) resulted in a live birth. Comparing successful pregnancies under intralipids with those with fetal loss, no significant differences have been noted.
Conclusion:
Intralipids could be an effective and safe therapy in women with unexplained recurrent miscarriages and infertility.
More Related Videos
08:29Author Spotlight: Multiplex Immunohistochemistry for Understanding Immune Regulation by Uterine NK Cells in Pregnancy
Published on: October 25, 2024
05:46Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
Published on: January 17, 2019
